BioMed Research International / 2013 / Article / Tab 2

Research Article

Off-Label Use of Ondansetron in Pregnancy in Western Australia

Table 2

Characteristics of children of women dispensed ondansetron any time during pregnancy.

  Ondansetron
  
  Nonondansetron
    = 98,062
OR (95% CI)
% %

Singleton24191.694,87296.70.4 (0.2–0.6)
Male12447.150,29551.30.8 (0.7–1.1)
Stillbirths<51.16350.61.8 (0.6–5.5)
APGAR 5 mins < 6*<51.15760.62.0 (0.6–6.1)
Birth length 50 cm**17767.356,10057.21.4 (1.0–1.8)
Birth weight <2500 g**3011.47,0787.21.3 (0.8–2.2)
POBW below 111547.749,70852.40.8 (0.6–1.1)
Resuscitated at birth12547.542,37643.21.2 (0.9–1.5)
Any birth defect166.14,7494.81.3 (0.8–2.1)
Any major birth defect124.63,9754.11.1 (0.6–2.0)
Any major birth defect, first trimester exposure***104.73,9754.11.2 (0.6–2.2)

POBW: proportion of optimal birth weight.
*Live births only.
**Adjusted for gestational age, smoking during pregnancy, SEIFA, sex, and parity.
*** children of a mother dispensed ondansetron in T1.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.